It is well established that N-terminal inhibition of HSP90 is effective in inhibiting tumour cell activity in vitro and 18 N-terminal inhibitors of HSP90 have been developed with clinical evaluation (Patel et al., 2013). The gene discussed is HSP90AA1; the disease is neoplasm.